Proteostasis Expands C-Suite, Adds Three New Execs

Xconomy Boston — 

Cambridge, MA-based Proteostasis Therapeutics (NASDAQ: PTI) appointed three new members to its executive team. James DeTore (Bluebird Bio’s (NASDAQ: BLUE) former chief financial officer) is Proteostasis’s new CFO; Geoffrey Gilmartin (most recently a medical lead at AstraZeneca) is the company’s chief development officer; and Marija Zecevic (founder of consulting firm Zebra Ventures) is heading up Proteostasis’s business development efforts.